Markets:

Overview

News

Currencies

International

Treasuries

ADC Therapeutics SA Common Shares (NY:ADCT)

3.540 -0.020 (-0.56%)

Official Closing Price Updated: 7:00 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >

Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022 ↗

November 09, 2022

Upgrades

Via Benzinga

Analyst Ratings for ADC Therapeutics ↗

November 09, 2022

Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter:

Via Benzinga

ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

November 08, 2022

From ADC Therapeutics SA

Via Business Wire

Analyst Ratings for ADC Therapeutics ↗

September 09, 2022

Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter:

Via Benzinga

Expert Ratings for ADC Therapeutics ↗

September 09, 2022

ADC Therapeutics (NYSE:ADCT) has observed the following analyst ratings within the last quarter:

Via Benzinga

ADC Therapeutics: Q2 Earnings Insights ↗

August 09, 2022

ADC Therapeutics (NYSE:ADCT) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

November 07, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting

November 03, 2022

From ADC Therapeutics SA

Via Business Wire

IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma

November 02, 2022

From ADC Therapeutics SA

Via Business Wire

November 02, 2022

From IGM Biosciences, Inc.

Via GlobeNewswire

ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer

November 01, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022

October 31, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)

September 21, 2022

From ADC Therapeutics SA

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022 ↗

September 21, 2022

Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago...

Via Benzinga

ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

September 16, 2022

From ADC Therapeutics SA

Via Business Wire

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm

September 14, 2022

From The Schall Law Firm

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm

September 13, 2022

From The Schall Law Firm

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 ↗

September 09, 2022

Upgrades

Via Benzinga

Where ADC Therapeutics Stands With Analysts ↗

September 09, 2022

Over the past 3 months, 4 analysts have published their opinion on ADC Therapeutics (NYSE:ADCT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

ADC Therapeutics to Participate in Morgan Stanley’s 20th Annual Global Healthcare Conference

September 06, 2022

From ADC Therapeutics

Via Business Wire

AMC Entertainment, Pharvaris And Some Other Big Stocks Moving Lower On Monday ↗

August 22, 2022

Via Benzinga

ADC Therapeutics Announces $175 million Senior Secured Term Loan from Owl Rock and Oaktree and Settlement of Existing Senior Secured Convertible Notes

August 15, 2022

From ADC Therapeutics SA

Via Business Wire

Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday ↗

August 15, 2022

Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results.

Via Benzinga

ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

August 09, 2022

From ADC Therapeutics SA

Via Business Wire

Earnings Outlook For ADC Therapeutics ↗

August 08, 2022

ADC Therapeutics (NYSE:ADCT) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. Analysts estimate that ADC...

Via Benzinga

ADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on August 9, 2022

August 02, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumors

July 27, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Rituximab in First-Line Diffuse Large B-Cell Lymphoma

July 20, 2022

From ADC Therapeutics SA

Via Business Wire

Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial

July 11, 2022

From ADC Therapeutics SA

Via Business Wire

Why ADC Therapeutics Shares Are Rising Today ↗

July 08, 2022

ADC Therapeutics SA (NYSE: ADCT) shares are trading higher by 11.56% to $10.23 Friday afternoon after the company entered into an exclusive license agreement with Swedish Orphan Biovitrum for the...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.